[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1243943A1 - 使用抗IL-1α抗體治療癌症 - Google Patents

使用抗IL-1α抗體治療癌症

Info

Publication number
HK1243943A1
HK1243943A1 HK18103522.1A HK18103522A HK1243943A1 HK 1243943 A1 HK1243943 A1 HK 1243943A1 HK 18103522 A HK18103522 A HK 18103522A HK 1243943 A1 HK1243943 A1 HK 1243943A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
antibodies
immunization
antibody
Prior art date
Application number
HK18103522.1A
Other languages
English (en)
Inventor
J‧賽瑪德
Original Assignee
埃克斯生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 埃克斯生物科技公司 filed Critical 埃克斯生物科技公司
Publication of HK1243943A1 publication Critical patent/HK1243943A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18103522.1A 2006-05-22 2018-03-13 使用抗IL-1α抗體治療癌症 HK1243943A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80216606P 2006-05-22 2006-05-22

Publications (1)

Publication Number Publication Date
HK1243943A1 true HK1243943A1 (zh) 2018-07-27

Family

ID=38670649

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103522.1A HK1243943A1 (zh) 2006-05-22 2018-03-13 使用抗IL-1α抗體治療癌症

Country Status (15)

Country Link
US (3) US20100040574A1 (zh)
EP (1) EP2109623B1 (zh)
JP (3) JP2009537628A (zh)
CN (3) CN101472948A (zh)
AT (1) ATE528319T1 (zh)
AU (1) AU2007252990B2 (zh)
CA (1) CA2652870C (zh)
CY (1) CY1112288T1 (zh)
DK (1) DK2109623T3 (zh)
ES (1) ES2374845T3 (zh)
HK (1) HK1243943A1 (zh)
PL (1) PL2109623T3 (zh)
PT (1) PT2109623E (zh)
SI (1) SI2109623T1 (zh)
WO (1) WO2007135546A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109187944A (zh) * 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102112154B (zh) * 2008-05-30 2013-10-30 埃克斯生物科技公司 白细胞介素-1α抗体及使用方法
WO2010030979A2 (en) * 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes
TWI522365B (zh) 2010-05-14 2016-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
AU2015201228B2 (en) * 2010-08-23 2016-02-11 Xbiotech Inc. Treatment for neoplastic diseases
DK2608808T3 (en) * 2010-08-23 2017-04-24 Xbiotech Inc TREATMENT OF NEOPLASTIC DISEASES
AU2015271978B2 (en) * 2010-08-23 2017-10-26 Xbiotech Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN110382001A (zh) 2017-02-16 2019-10-25 埃克斯生物科技公司 化脓性汗腺炎的治疗
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095676A1 (en) * 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JPH06339394A (ja) * 1986-11-13 1994-12-13 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−１αに対するモノクローナル抗体
US5034316A (en) * 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
JPH02157231A (ja) * 1988-12-07 1990-06-18 Bio Kagaku Kenkyusho:Kk 細胞増殖抑制剤
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JPH08502300A (ja) * 1992-10-14 1996-03-12 スターリング ウィンスロップ アイエヌシー． 治療および診断像形成組成物および方法
EP0614984B2 (en) * 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
TWI367102B (en) * 2002-09-06 2012-07-01 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) * 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (en) * 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
CN109187944A (zh) * 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
AU2007251239B2 (en) * 2006-05-15 2013-08-22 Xbiotech Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
RS54163B1 (en) * 2006-05-30 2015-12-31 Genentech Inc. ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE
CN102112154B (zh) * 2008-05-30 2013-10-30 埃克斯生物科技公司 白细胞介素-1α抗体及使用方法
WO2010030979A2 (en) * 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes

Also Published As

Publication number Publication date
DK2109623T3 (da) 2012-01-30
US20160159899A1 (en) 2016-06-09
AU2007252990B2 (en) 2011-10-27
JP2009537628A (ja) 2009-10-29
PT2109623E (pt) 2012-01-12
US20190169287A1 (en) 2019-06-06
US20100040574A1 (en) 2010-02-18
WO2007135546A2 (en) 2007-11-29
ATE528319T1 (de) 2011-10-15
JP5992843B2 (ja) 2016-09-14
CA2652870C (en) 2014-12-02
EP2109623B1 (en) 2011-10-12
CA2652870A1 (en) 2007-11-29
SI2109623T1 (sl) 2012-05-31
CN107158376A (zh) 2017-09-15
CY1112288T1 (el) 2015-12-09
JP6359492B2 (ja) 2018-07-18
CN102580086A (zh) 2012-07-18
ES2374845T3 (es) 2012-02-22
EP2109623A2 (en) 2009-10-21
JP2015166401A (ja) 2015-09-24
CN101472948A (zh) 2009-07-01
AU2007252990A1 (en) 2007-11-29
PL2109623T3 (pl) 2012-03-30
JP2013126990A (ja) 2013-06-27
WO2007135546A3 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
EP2103628A4 (en) MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
MY150756A (en) Tumor theraphy with an anti-vegf antibody
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
NZ601588A (en) Methods for treating breast cancer
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue